A 55-year-old woman with a 20-year history of type 2 diabetes mellitus presents with serum creatinine of 2.4 mg/dL (eGFR 28 mL/min/1.73 m²) and urine albumin:creatinine ratio of 850 mg/g. Her blood pressure is 148/92 mmHg on lisinopril 10 mg daily. Which additional agent has demonstrated the greatest cardiorenal protective benefit in this patient?
- A Non-dihydropyridine calcium channel blocker (diltiazem)
- B Add losartan for dual RAAS blockade
- C Aldosterone antagonist (spironolactone)
- D Sodium-glucose cotransporter-2 inhibitor (SGLT2i) ✓
Explanation
SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin) have demonstrated robust cardiorenal protective effects in diabetic kidney disease independent of glycemic control, reducing the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death. The CREDENCE and DAPA-CKD trials established their benefit even at eGFR down to 25 mL/min. Dual RAAS blockade (ACEi + ARB) is contraindicated due to increased risk of acute kidney injury and hyperkalemia without additional cardiovascular benefit (ONTARGET trial). Non-dihydropyridine CCBs reduce proteinuria modestly but lack the large outcome trial data of SGLT2i. Spironolactone carries significant hyperkalemia risk at this level of CKD.
Reference: Harrison's Principles of Internal Medicine, 21st ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.